What is he best known for?
The fields of study he is best known for:
Cancer research, Leukemia, Myeloid leukemia, Stem cell and Kinome are his primary areas of study.
Alessandro Datti has researched Cancer research in several fields, including Cell culture, Protein kinase B, Kinase and Internal medicine.
The various areas that Alessandro Datti examines in his Myeloid leukemia study include Antileukemic agent and Pharmacology.
His work deals with themes such as Cell and Mitochondrion, which intersect with Stem cell.
His study in Kinome is interdisciplinary in nature, drawing from both Regulator, Serrate-Jagged Proteins and Small interfering RNA.
His biological study spans a wide range of topics, including Cancer stem cell, Virology and Mitochondrial biogenesis.
His most cited work include:
- Functional Genomics Reveals a BMP-Driven Mesenchymal-to-Epithelial Transition in the Initiation of Somatic Cell Reprogramming (800 citations)
- Inhibition of Mitochondrial Translation as a Therapeutic Strategy for Human Acute Myeloid Leukemia (369 citations)
- Inhibition of Mitochondrial Translation as a Therapeutic Strategy for Human Acute Myeloid Leukemia (369 citations)
What are the main themes of his work throughout his whole career to date?
Alessandro Datti mainly focuses on Cancer research, Biochemistry, Cell biology, Pharmacology and Cell culture.
His Cancer research research incorporates elements of Head and neck cancer, Apoptosis, Cell cycle, Kinase and In vivo.
His Biochemistry research is multidisciplinary, incorporating elements of Molecular biology and Bone resorption.
Alessandro Datti works in the field of Cell biology, focusing on Mitochondrion in particular.
Alessandro Datti combines subjects such as Daunorubicin, Leukemia, Myeloid leukemia and Stem cell with his study of Pharmacology.
In Myeloid leukemia, Alessandro Datti works on issues like Progenitor cell, which are connected to Mitochondrial biogenesis.
He most often published in these fields:
- Cancer research (57.83%)
- Biochemistry (24.70%)
- Cell biology (19.28%)
What were the highlights of his more recent work (between 2015-2021)?
- Cancer research (57.83%)
- Cell culture (16.87%)
- In vivo (14.46%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Cancer research, Cell culture, In vivo, Cell biology and Cell cycle.
His work carried out in the field of Cancer research brings together such families of science as Cancer, Breast cancer, Anaplastic thyroid cancer, Cell growth and Kinase.
The Cell culture study combines topics in areas such as Head and neck cancer, Chemotherapy, Inhibitory postsynaptic potential, Pathology and High-throughput screening.
His In vivo study combines topics from a wide range of disciplines, such as Targeted therapy and Syk.
His work in the fields of Cell biology, such as Mitochondrion, overlaps with other areas such as Germination.
The study incorporates disciplines such as Tyrosine kinase and Myeloid leukemia in addition to Pharmacology.
Between 2015 and 2021, his most popular works were:
- RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation (64 citations)
- Multilayered Control of Alternative Splicing Regulatory Networks by Transcription Factors (62 citations)
- Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer. (37 citations)
In his most recent research, the most cited papers focused on:
His primary areas of investigation include Cancer research, PTEN, Breast cancer, PI3K/AKT/mTOR pathway and Cell biology.
Alessandro Datti interconnects Soft tissue sarcoma, Protein kinase B, Cell growth, Cancer cell and Triple-negative breast cancer in the investigation of issues within Cancer research.
His Triple-negative breast cancer research is multidisciplinary, incorporating perspectives in Cyclin-dependent kinase 1, Wee1, Regulation of gene expression and Kinome.
His PTEN research incorporates themes from Metastasis, Claudin-Low, Surgical oncology, Transplantation and Adenocarcinoma.
Alessandro Datti has researched PI3K/AKT/mTOR pathway in several fields, including Bioinformatics, Leiomyosarcoma, Doxorubicin, Sarcoma and Kinase.
He combines subjects such as Downregulation and upregulation and Neuroprotection with his study of Cell biology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
